2,537 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Lombard Odier Asset Management Switzerland SA

Posted by Stanley Muller on Jul 28th, 2026

Lombard Odier Asset Management Switzerland SA bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the first quarter, Holdings Channel reports. The firm bought 2,537 shares of the company’s stock, valued at approximately $1,426,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the 3rd quarter valued at $26,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares during the period. Wormser Freres Gestion lifted its position in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 47 shares during the last quarter. Finally, WealthCollab LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on IDXX. UBS Group dropped their price objective on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a research note on Monday. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $749.00.

View Our Latest Analysis on IDXX

IDEXX Laboratories Trading Up 2.2%

IDXX stock opened at $556.20 on Tuesday. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $556.48 and its 200-day moving average is $593.74. The firm has a market cap of $43.87 billion, a P/E ratio of 40.96, a P/E/G ratio of 2.98 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.